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Abstract
Machine learning methods applied to complex biomedical data has enabled the
construction of disease signatures of diagnostic/prognostic value. However, less
attention has been given to understanding disease heterogeneity. Semi-supervised
clustering methods can address this problem by estimating multiple transforma-
tions from a (e.g. healthy) control (CN) group to a patient (PT) group, seeking to
capture the heterogeneity of underlying pathlogic processes. Herein, we propose a
novel method, Smile-GANs (SeMi-supervIsed cLustEring via GANs), for semi-
supervised clustering, and apply it to brain MRI scans. Smile-GANs first learns
multiple distinct mappings by generating PT from CN, with each mapping charac-
terizing one relatively distinct pathological pattern. Moreover, a clustering model
is trained interactively with mapping functions to assign PT into corresponding
subtype memberships. Using relaxed assumptions on PT/CN data distribution and
imposing mapping non-linearity, Smile-GANs captures heterogeneous differences
in distribution between the CN and PT domains. We first validate Smile-GANs
using simulated data, subsequently on real data, by demonstrating its potential
in characterizing heterogeneity in Alzheimer’s Disease (AD) and its prodromal
phases. The model was first trained using baseline MRIs from the ADNI2 database
and then applied to longitudinal data from ADNI1 and BLSA. Four robust subtypes
with distinct neuroanatomical patterns were discovered: 1) normal brain, 2) diffuse
atrophy atypical of AD, 3) focal medial temporal lobe atrophy, 4) typical-AD.
Further longitudinal analyses discover two distinct progressive pathways from
prodromal to full AD: i) subtypes 1 - 2 - 4, and ii) subtypes 1 - 3 - 4. Although
demonstrated on an important biomedical problem, Smile-GANs is general and
can find application in many biomedical and other domains.
1 Introduction
Numerous studies have been conducted via case-control group comparisons for neuroimaging
biomarkers tracking in brain diseases, such as Alzheimer’s Disease (AD)[1][2][3]. However, those
studies suffer from underpowered statistical inferences due to the violation of the underlying assump-
tion that each group population are relatively homogeneous pathologically, thus drawing inconsistent
conclusions across studies.
Better understanding of brain disease heterogeneity paves the road for precision diagnostics, as
umbrella disease classification can be broken down to more precisely and homogeneously defined
pathologies. Machine learning (ML) has shown great promise in this area. Semi-supervised clustering
methods were recently proposed to address this issue[4] [5]. Instead of clustering directly in patient
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Figure 1: Schematic diagram and network architectures. (A): General idea behind Smile-GANs (B):
Schematic diagram of Smile-GANs. CN: cognitive normal control, PT: patient, SUB: subtype (C):
Network architecture of three functions: blue arrow represents one linear transformation followed by
one leaky relu function, green arrow represents one linear transformation followed by one softmax
function, red arrow represents only one linear transformation.
population based on similarity/dissimilarity, semi-supervised methods seek to cluster by multiple
transformations or patterns between the subgroup of patients and a reference group (e.g., cognitive
normal control (CN) group). This way, they attempt to avoid capturing uninformative variations
due to various confounds, and focus on variation of disease effects. Nevertheless, their limitations
lie in that the clustering either relies on the SVM-based classification accuracy [4] or has strong
assumptions on data distribution and transformation linearity [5]. More recently, deep learning (DL)
has made a big leap in medical imaging applications [6]. Generative adversarial networks (GANs) are
well-known for modeling a distribution from samples [7]. This attribute makes it natural for learning
difference in distribution of two groups of data and drives the current work to explore its potential for
semi-supervised clustering.
To address the aforementioned limitations, we proposed a novel method, Smile-GANs: SeMi-
supervIsed cLustEring via GANs, for parsing disease heterogeneity. Smile-GANs aims to tackle
heterogeneity by transforming data from CN domain X to patient (PT) domain Y . The first novelty
here is to learn several distinct mappings fi such that the distributions of fi(X) are not distinguishable
from the distribution of Y . By focusing on the difference between CN and subpopulations/subtypes
in PT domain, each mapping can represent a unique neuroanatomical pattern related to disease
effects. For that purpose, Smile-GANs borrowed the idea of Cycle-GAN [8] and Cluster-GAN [9],
constructing one-to-many mappings from CN to PT domain with unpaired data. Moreover, those
multiple mappings offer interpretable neuroanatomical patterns for each subtype. The second novelty
of Smile-GANs is the interactive training of the mapping function and a clustering function which
transform Fake-PT domain back to the subtype domain, allowing for quick and accurate clustering of
unseen PT data. The third novelty is the construction of effective monitoring criteria for training of
Smile-GANs on the lower dimensional representation of imaging data, guaranteeing the performance
of saved models in mapping and clustering.
We first validate the potential of Smile-GANs on simulated data with the known number of clus-
ters/subtypes (K) and their atrophy patterns. We demonstrate that Smile-GANs both accurately
clusters pre-selected subtypes and discovers their corresponding simulated atrophy patterns. We
then apply Smile-GANs to Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 baseline data and
reveal four reproducible subtypes in AD and mild cognitive impairment (MCI) subjects with distinct
clinical profiles. Further analyses indicate two different disease progressive pathways by applying the
trained model to ADNI 1 and Baltimore Longitudinal Study of Aging (BLSA) longitudinal data.
2
2 Method
The general structure of Smile-GANs is shown in Fig. 1. The essential element of the model is to
learn one-to-many mappings from CN domain X to PT domain Y . The idea is equivalent to learning
one mapping function f which generates fake PT data y′ = f(x, z) from joint domain X × Z, while
enforcing the equality between PT domain Y and Fake-PT domain Y ′. Here, Z is referred as the
subtype (SUB) domain and we denote data distributions in four domains as x ∼ pCN(x), y ∼ pPT(y),
y′ ∼ pY ′and z ∼ pSUB(z), respectively. The variable z ∈ Z, independent from x, can take a value
from 1 to K (i.e., the number of subtypes/mappings) with equal probability. In addition, an adversarial
discriminator D is introduced to distinguish between real PT y and fake PT y′. On top of that, we
introduce another function g from domain Y ′ to Z which serves both as a regularization term and a
clustering function from PT domain to SUB domain for clustering membership assignment.
The objective contains two types of losses. First, the adversarial loss [7] serves to match the
distribution of data in Fake-PT domain to real data in PT domain. Secondly, the regularization loss
includes the change loss and the cluster loss. Specifically, the change loss controls the distance
of transformation, with the assumption that disease effects should not greatly change the original
anatomy. The cluster loss controls the independence among multiple mappings and guarantees
the clustering accuracy of function g on patient data. We give more details of the objective in the
following sections.
2.1 Adversarial Loss
The adversarial loss is applied for training of discriminator D and the mapping function f , which can
be written as:
LGAN(D, f) = Ey∼pPT [log(D(y))] + Ez∼pSUB,x∼pCN [log(D(f(x, z)))]
= Ey∼pPT [log(D(y))] + Ey′∼pY’ [log(D(y
′))]
The mapping f attempts to transform CN to corresponding fake PT data so that they follow similar
distributions as real PT data. The discriminator D, representing the probability that y come from the
real data rather than generator, is trying to identify the fake PT data from the real PT data. Therefore,
the discriminator attempts to maximize the adversarial loss function while the mapping f attempts to
minimize against it. The training process can be denoted as:
min
f
max
D
LGAN(D, f) = Ey∼pPT [log(D(y))] + Ey′∼pY’ [log(D(y
′))]
2.2 Regularization Loss
The change loss is to control the distance of transformations. As our model is applied to a lower
dimensional representation of imaging data, region of interests (ROIs), we assume that only some
specific regions will be affected by the disease process, whereas the rest should remain unchanged.
To encourage sparsity, we define the change loss to be the l1 distance between the fake PT data and
the original CN data: Lchange(f) = Ex∼pCN,z∼pSUB [||f(x, z)− x||1].
Moreover, we formulate the cluster loss as Lcluster(f, g) = Ex∼pCN,z∼pSUB [||g(f(x, z)) − z||2]. By
controlling the distance between the sampled SUB variable z and the reconstructed SUB variable, we
enforce the function g ◦ f to be an Identity function of z. This leads to the first property that f(a, z)
is an injective mapping for fixed x = a such that different values of SUB variable z will transform
the same CN data to different PT data. With minimization of the cluster loss, there arises the second
property: for z1 6= z2 and different CN data, x1 6= x2 f(x1, z1) 6= f(x2, z2). These two properties
of the mapping function f are important, since they guarantee that the SUB variable z is not ignored
during training process and that there is no intersection among mapping directions (i.e., one PT data
is only assigned to one subtype).
More importantly, with the assumption that pPT = pY’ after f and g are properly trained [7], we
can derive the equality between PT domain Y and Fake-PT domain Y ′ and thus for y ∼ pPT,
g(y) = g(y′) = g(f(x, z)) = z, where z ∼ pSUB indicates the subtype membership. In other words,
g can be a clustering function for quickly clustering unseen data.
3
2.3 Full Objective
With the aforementioned losses, we can write the full objective as:
L(D, f, g) = LGAN(D, f) + µLchange(f) + λLcluster(f, g)
with µ and λ be two parameters controlling the relative importance of each Loss function during the
training process. Through this objective, we want to find the mapping f and the clustering function g
such that:
f, g = argmin
f,g
max
D
L(D, f, g)
3 Implementation details
3.1 Network Architecture
For faster convergence of model in implementation, the mapping function, instead of directly
transforming the CN data to the fake PT data, first learns a change in the CN data and takes the sum
of them to obtain the fake PT data. Therefore, the architecture of the mapping function f can be
divided into two phases as shown in Fig. 1(C). In the first phase, the CN data and the SUB variable are
mapped to latent representations with same dimension through encoder and decoder [10], respectively.
The second phase has one decoding structure mapping the dot-product of two representations to the
change x˜, which is added to the CN data x to acquire the fake PT data. The discriminator D and the
clustering function g have similar encoding structures, with D mapping PT/fake PT data to prediction
vector with dimension 2 while the encoder g mapping the fake PT data to a SUB representation.
3.2 Training Details
First, we rewrite the procedure in section 2.1 as: minD LGAN(D) = Ey∼pPT [(D(y) − 1)2] +
Ez∼pSUB,x∼pCN [D(f(x, z))
2] and minf LGAN(f) = Ez∼pSUB,x∼pCN [D(f(x, z) − 1)2]. Using this
least square loss instead of original log likelihood boosts stability of the training process [11]. Second,
the SUB variable z is constructed as a one-hot latent variable with dimension K instead of one single
value and thus the cross-entrophy loss is computed for the cluster loss defined in section 2.2.
We set two parameters to be µ = 5 and λ = 9 for all experiments. Also,we performed gradient clip
for each iteration to avoid the explosion of gradient during the training process. For optimization, we
used ADAM optimizer [12] with learning rate 0.0004 for Discriminator D and 0.002 for mapping f
and clustering function g. β1 and β2 are 0.5 and 0.999, respectively. More details about architectures
and training procedures are present in Supplementary.
3.3 Stopping Criteria
For real application, since the ground truth of subtypes is unknown, we adopt an approximation of
the Wasserstein distance (WD) [13] as one metric for monitoring the training process and choosing
the stopping point. For Smile-GANs, instead of deriving WD from optimization as the original paper
introduced, we used the closed form formula to compute the distance. For stopping criteria, we assume
that, in CN domain and in all subpopulations of PT domain, the lower dimensional representation of
each data point (ROIs) is sampled from a multivariate Gaussian distribution. Though this assumption
might be strong, it does enable us to estimate the WD quickly.
To be more specific, for each mapping direction z = i and for all samples in CN domain X =
{x1, x2, · · · , xn}, we calculate the mean vector mi1 and covariance matrix Ci1 of f(X, i). Also, from
samples in PT domain Y, we take out the subset Yi = {yj}i such that g(yj) = i and calculate the
mean vector mi2 and covariance matrix C
i
2. With mean vectors and covariance matrices, we can
compute the 2nd Wasserstein distance using the formula for two multivaraite gaussian measure:
W2(µf(X,i), µYi) = ||mi1 −mi2||22 + trace(Ci1 + Ci2 − 2(Ci2
1/2
C1
iCi2
1/2
)1/2)
If we further assume that all features are independent, we can derive diagonal covariance matrices
which make the computation even faster and, based on our experiments, this assumption does not
affect monitoring training process.
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Moreover, to deal with rare cases when inconsistencies exist between WD and model performance,
we also derive two other metrics: alteration quantity (AQ), which represents the number of subjects
whose subtype memberships alter in the last five epochs. A small AQ represents high stability of the
model. Lastly, the cluster loss, indicating the performance of clustering function g, is also considered
as part of the stopping criteria.
4 Experiments
4.1 Experiments on Simulated Data
Simulated Data Generation Simulated data were generated in a low dimensional space (i.e., 145
ROIs). For each subject, the 145 ROIs were simulated by sampling from a normal distribution
N (1, 0.1). In total, 1200 subjects were generated independently and then randomly split into two
half-split sets, with each (600) being CN and pseudo-PT group, respectively. The atrophy simulation
was only introduced for pseudo-PT subjects, which were further divided into 3 subtypes with the
same number of subjects (200). For each subtype, the values of specific pre-selected ROIs were
deceased by 10 to 20% randomly to simulate the severity of the atrophy. Moreover, to simulate
covariate effects, we randomly sampled 200 subjects from both CN and pseudo-PT respectively and
decreased the values by 10 to 20% in some other ROIs. The simulation ground truth for the covariate
patterns and the 3 subtypes are shown in Fig. 2(c)(i) and (ii), respectively. Note that overlapping of
ROIs across subtypes was imposed to better follow the nature of atrophy.
Experiments on Simulated Data To add variability of the clustering performance, we repeated the
simulated data generation and ran the experiment independently 20 times. We first investigated the
potential of WD for monitoring training process. Then we compared the clustering performance
of Smile-GANs with traditional K-means [14] and Gaussian Mixtrue Model (GMM) [15]. Finally,
the mapping function (f ) of Smile-GANs can be used to visualize the subtypes’ atrophy patterns
captured for fake PT data generation. We calculated the mean difference between CN and fake PT in
K mapping directions and inspected ROIs with significant decreasing in values.
4.2 Experiments on Real Data
Data and Image Processing For experiments on real data, we first included 297 CN and 602
AD/MCI subjects for baseline T1-weighted (T1) MRIs from ADNI 2 database. The trained model
was further applied to longitudinal data, undergoing more than one visit in 2 to 23 years from the
baseline, from ADNI1 and BLSA dataset. The longitudinal data consist of 1323 CN and 610 MCI/AD
subjects. For all T1 MRIs, brain tissue segmentation was performed using a multi-atlas segmentation
technique [16] and 145 ROIs were derived as features for Smile-GANs. Those features were first
harmonized to remove site effect [17], and then age and gender effects were corrected in a pooled
sample of matched controls using a voxel-wise linear model. Moreover, gray matter (GM) tissue
maps [18] were also segmented for voxel-wise statistical mapping.
Experiments on baseline data We first chose the optimal K. Smile-GANs was run for 20 times
for different K (K = 2 to 5). The optimal K was chosen by the highest Adjusted Rand Index (ARI)
[19], which quantifies the clustering stability across the 20 repetitions/models, and also guided by
prior knowledge in literature. For each model, it assigns each patient to its corresponding subtype
membership with the highest probability. The final clustering membership was determined by a
consensus clustering strategy across the 20 models. The mapping function (f ) of Smile-GANs
was first applied to visualize the subtypes’ atrophy patterns captured for fake PT data generation.
Moreover, Voxel-wise group comparison between CN and subtypes of real PT data were performed
with AFNI 3dttest [20] with GM tissue maps [18].
Experiments on longitudinal data The trained 20 models from ANDI2 was applied to longitudinal
data for determining the subtype membership for scans from all visits. Note that only subjects who
were consistently assigned into the same subtype from more than 60% of the models (i.e., 12) were
finally taken into account, which were studied for the disease longitudinal progression pathways from
prodromal to full AD stages.
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Figure 2: Results on simulated data. (A): Clustering training process monitoring with Wasserstein
distance (WD). Clustering error = 1 - clustering accuracy. (B): Comparison of clustering performance
across Smile-GANs, K-means and Gaussian mixture model (GMM). (C): The mapping function
(f ) of Smile-GANs discovers (iii) the ground truth of subtypes’ pure atrophy patterns (ii) while not
confounded by covariate patterns (i). Each mapping direction represents one subtype. Only the ROIs
whose values decreasing over 5% are displayed.
5 Results
5.1 Results on simulated data
WD for training monitoring Fig. 2(a) shows the change of WD and clustering error (i.e., 1 -
clustering accuracy) during training. Generally, the two metrics are consistent in monitoring the
training process. Therefore, WD could be used as a surrogate of clustering accuracy when the latter is
not available in real applications. Note that inconsistencies at the beginning of training or oscillations
exist. Such circumstances can be filtered out by other two metrics, alteration quantity (AQ) and
cluster loss. We propose to use WD, along with AQ and cluster loss, as metrics for monitoring the
training process.
Clustering performance comparison across models Fig. 2(b) shows the clustering accuracy of
Smile-GANs, K-means and GMM. Smile-GANs (0.916± 0.025) plainly outperforms the K-means
(0.615± 0.028) and GMM (0.611± 0.039) for clustering those three subtypes.
Mapping function for visualization of atrophy patterns Fig. 2(c) shows the atrophy patterns
captured by all different mapping directions (K=3). Smile-GANs can automatically identify the
ground truth of atrophy patterns, while not capturing any covariate effects. Together with Fig. 2(b),
our results clearly indicates that Smile-GANs can not only cluster subtypes accurately, but also
automatically identify the underlying atrophy patterns for better interpretation.
5.2 Results on ADNI2 Baseline Data
For baseline experiments, the stopping criteria during training is that the highest WD of all mappings,
AQ and cluster loss are smaller than 0.22, 35 and 0.001, respectively. The maximum number of
epochs was set to be 6000 and models failing to converge were discarded.
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Figure 3: Result on baseline ADNI2. (A): Clustering stability across different K with adjusted rand
index (ARI). (B): Atrophy patterns of subtypes captured by mapping function (f ) of Smile-GANs for
data generation. Only the ROIs whose values decreasing over 2.5% are displayed. MD: mapping
direction. (C): Voxel-wise statistical comparison between subtype and CN. FDR method with p-value
threshold of 0.05 was used for the correction of multiple comparison.
Clustering stability for optimal K Fig. 3(A) shows the results of ARI for different K. Though K=2
gave the highest ARI, Smile-GANs roughly divided PT into one subtype with barely atrophy and
another subtype with whole-brain atrophy. Based on the prior knowledge from the literature [4][5]
and relatively higher ARI for K=4, we therefore selected K=4 for following experiments.
Neuroanatomical Heterogeneity between Subtypes and CN Fig. 3(B) shows regions with atrophy
identified by the four mapping directions for fake data generation (Detail of the name of ROIs are
present in Supplementary). Fig. 3(C) shows the voxel-based group comparison results for each
subtype group of real subtypes versus CN group. The two approaches converge to the same findings:
i) Subtype 1, referred as normal brain, exhibits no atrophy over the whole brain; ii) Subtype 2, denoted
as diffuse atrophy atypical of AD, shows widespread atrophy patterns in frontal and temporal lobe,
but medial temporal lobe is spared; iii) Subtype 3, referred as focal medial temporal lobe atrophy,
shows localized atrophy in the hippocampus and the anterior-medial temporal cortex; iv) Subtype 4,
denoted as typical-AD, displays severe atrophy over the whole brain.
Clinical Characteristics of clustering subtypes The clinical characteristics of the four subtypes are
summarized in Table 1. Most of subjects in subtype 1 are MCI subjects while more than half of
AD subjects are in subtype 4. All three clinical variables (i.e., Abeta, T-tau and WML) of subtype 1
significantly differ to those of the other subtypes. Subtype 2 and 3 also show significant difference
in Abeta (p=0.018) and T-tau (p=0.003). Though not significant, subtype 2 has substantially higher
WML load than subtype 3.
5.3 Results on Longitudinal Data
Table 2 shows the subtype membership conversion from baseline assignment to future longitudinal
assignment using longitudinal AD, MCI and CN subjects. Most of subjects in subtype 1 at baseline
remained unchanged for future membership assignment, but some of them progressed to other
subtypes in later visits. A substantial proportion of subjects who were assigned into subtype 2 and 3
at baseline finally transformed into subtype 4, but the transformation between these two subtypes are
very rare.
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Table 1: Clinical characteristics of clustering subtypes. WML: white matter lesion
Subtype 1 Subtype 2 Subtype 3 Subtype 4
AD 5(2.6%) 15(15%) 29(29.6%) 89(52.0%)
MCI 185(97.4%) 85(85%) 69(70.4%) 82(48.0%)
Median Abeta 192.0 158.5 142.0 135.0
Median T-tau 62.9 74.6 98.1 96.0
Median WML 926.4 3152.4 754.8 11054.9
Table 2: Results on longitudinal conversions of clustering membership. Subjects from each subtype,
determined by the initial clustering membership at their first visit, were reassigned for the membership
at their future visits.
Initial
membership
Future membership
Subtype 1 Subtype 2 Subtype 3 Subtype 4
Subgroup 1 83.7%(860/1027) 9.3%(96/1027) 6.23%(64/1027) 3.2%(33/1027)
Subgroup 2 3.8%(16/413) 74.8%(309/413) 2.17%(9/413) 20.5%(85/413)
Subgroup 3 4.2%(11/260) 1.9%(5/260) 62.7%(163/260) 32.3%(84/260)
Subgroup 4 0.2%(1/469) 0.8%(4/469) 0.8%(4/469) 98.2%(460/469)
Alternatively, we also studied the change of probability for subtype membership assignment in AD
and MCI subjects in a window of 6 years (Fig. 4). For subjects assigned into subtype 1 at baseline,
they show increasing probabilities belonging to subtype 2 or 3 at early stage, and then to subtype
4 at later stage (Fig. 4 (a)). For subjects of subtype 2 and 3, they all have increasing probabilities
belonging to subtype 4 in later visits (Fig. 4 (b) and (c)). Those results (Table 2 and Fig. 4) potentially
indicate two distinct longitudinal disease progression pathways: i) subtypes 1 - 2 - 4, and ii) subtypes
1 - 3 - 4.
6 Conclusion
In this study, we proposed a novel method, Smile-GANs, for parsing disease heterogeneity in
interpretable ways that support precision diagnostics. Smile-GANs found 4 robust subtypes differing
in clinical profiles and unveiled two distinct longitudinal disease progression pathways. Though we
demonstrate our claims on the heterogeneity of AD, Smile-GANs is general and able to be applied to
other medical applications and domains. The direction of our future work is to extend the current
model to high-dimensional imaging data (i.e., voxel-wise features) to better capture multivariate
patterns of disease heterogeneity.
Broader Impact
The current work has the following potential positive impacts. First, Simle-GANs provides a general
and principled way of capturing biological heterogeneity in an interpretable way, hence it can help in
mode precisely defining many diseases and pathologies, based on quantitative measures like imaging.
Herein we present AD as an example, and demonstrate how dissecting heterogeneity of this disease
and its prodromal stage can help us identify different paths to dementia. Second, the current work
potentially provides some reasoning for the failure of disease-modifying treatments in AD, which
might be more effective if applied to the right patient subpopulations. The breakdown of disease
heterogeneity enables to refine relatively unique pathologic populations and eventually benefit future
therapeutic trials. Meanwhile, it should be mentioned that any predictive machine learning model runs
risk of misclassification, our work is no exception. However, our model primarily seeks to stratify the
patient population, avoiding the detrimental false positive screening results for participants.
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Figure 4: Results on longitudinal conversions of clustering membership. The probability of mem-
bership conversion to other subytpes are shown to track the disease progression. Each subject was
initially assigned, at its first visit, as subtype 1, 2, 3 or 4, corresponding to (A), (B), (C) and (D)
respectively.
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7 Supplementary
7.1 Network Architecture
Detailed architectures of mapping function, clustering function and discriminator are provided in
table 3 and table 4.
Table 3: Architecture of mapping function f
Layer Input Size Bias Term leaky relu α Output Size
Phase1(Encoder) Linear1+Leaky-ReluLinear2+Leaky-Relu
145*1
72*1
No
No
0.2
0.2
72*1
36*1
Phase1(Decoder) Linear1+Sigmoid K*1 Yes NA 36*1
Phase2
Linear1+Leaky-Relu
Linear2+Leaky-Relu
Linear3
36*1
72*1
145*1
No
No
No
0.2
0.2
NA
72*1
145*1
145*1
Table 4: Architecture of discriminator D and clustering function g
Layer Input Size Bias Term leaky relu α Output Size
Discriminator
Linear1+Leaky-Relu
Linear2+Leaky-Relu
Linear3+Softmax
145*1
72*1
36*1
Yes
Yes
Yes
0.2
0.2
NA
72*1
36*1
2*1
Clustering
Linear1+Leaky-Relu
Linear2+Leaky-Relu
Linear3+Leaky-Relu
Linear4+Softmax
145*1
145*1
72*1
36*1
Yes
Yes
Yes
Yes
0.2
0.2
0.2
NA
145*1
72*1
36*1
K*1
7.2 Algorithm
Detailed training procedure of Smile-GANs is disclosed by Algorithm 1.
Algorithm 1: Smile-GANs training procedure. lc represents cross entropy loss and ei represents a
one hot vector with 1 at ith component.
while not meeting stopping criteria or reaching max_epoch do
for all batches {xi}mi=1,{yi}mi=1 do
sample m integers {ai}mi=1 with ai ∼ discrete-U(1,K) and let zi = eai
Update weights of discriminator D: Use ADAM to update θD with gradient:
∇θD 1m
∑m
i=i[(lc(D(yi), e1) + lc(D(f(xi, zi), e0)))]
Update weights of mapping function f: Use ADAM to update θf with gradient:
∇θf 1m
∑m
i=i[lc(D(f(xi, zi), e1))) + λlc(g(f(xi, zi), zi) + µ(||f(xi, zi)− xi||1)]
Update weights of clustering function g: Use ADAM to update θg with gradient:
∇θg 1m
∑m
i=i[λlc(g(f(xi, zi), zi) + µ(||f(xi, zi)− xi||1)]
end
end
7.3 ROIs names
Full names of ROIs shown in Fig. 3(B) are displayed in table 5.
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Table 5: Full names of ROIs
Abbr ROI Abbr ROI
RAC Right Accumbens Area RI Right Inferior Temporal Gyrus
LAC Left Accumbens Area LI Left Inferior Temporal Gyrus
RAm Right Amygdala LLO Left Lateral Orbital Gyrus
LAm Left Amygdala RMfc Right Medial Frontal Cortex
RH Right Hippocampus RMfg Right Middle Frontal Gyrus
LH Left Hippocampus LMo Left Middle Occipital Gyrus
LT Left Thalamus Proper RMt Right Middle Temporal Gyrus
LB Left Basal Forebrain LMt Left Middle Temporal Gyrus
RB Right Basal Forebrain ROp Right Opercular Part of the Inferior Frontal Gyrus
RAI Right Anterior Insula LOp Left Opercular Part of the Inferior Frontal Gyrus
LAI Left Anterior Insula RPh Right Parahippocampal Gyrus
RAO Right Anterior Orbital Gyrus LPh Left Parahippocampal Gyrus
RAn Right Angular Gyrus RPi Right Posterior Insula
LAn Left Angular Gyrus LPi Left Posterior Insula
LCo Left Central Operculum LPo Left Parietal Operculum
RE Right Entorhinal Area LPOr Left Posterior Orbital Gyrus
LE Left Entorhinal Area RPp Right Planum Polare
RFo Right Frontal Operculum LPt Left Planum Temporale
LFo Left Frontal Operculum RSt Right Superior Temporal Gyrus
RFu Right Fusiform Gyrus LSt Left Superior Temporal Gyrus
LFu Left Fusiform Gyrus RTm Right Temporal Pole
LTm Left Temporal Pole
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